09 September 2002
AIDS research in developing countries: do the ends justify the means?
Peter A. ClarkMed Sci Monit 2002; 8(9): ED5-16 :: ID: 13257
Abstract
Concrete ethical standards for human research are clearly stipulated in both international and national codes of ethics, and are meant to protect human subjects, especially the most vulnerable. A recent clinical study conducted from 1994 to 1997 by Dr. Thomas C, Quinn, M.D. has fueled the debate raging in the scientific community regarding the ethics of clinical AIDS research in developing countries. Quinn's conducted a community-based, randomized, controlled study of 15,127 rural Ugandans to determine whether intermittent antibiotic treatment to reduce the prevalence of other sexually transmitted diseases would also reduce the rate of HIV transmission. Subsequently, the study identified 415 couples in which one partner was HIV positive and one was initially HIV negative and followed them prospectively for up to 30 months. Researchers were not permitted to inform the seronegative partner of the HIV status of the other partner. As a result, 90 of the initially HIV negative partners (21.7%) seroconverted during a follow-up period of 30 months. To allow for research studies in developing countries that are not permitted in the United States appears to make the Third World equivalent to a 'research sweat shop'. Developing nations offer easy access to patients, reduced costs, and less stringent regulations. This appears to create a double standard for medical research that is both ethically and humanly unacceptable, especially when other viable option exist. To allow relativism to seep into the international and national ethical standards will open the door to an idea that condones the possible abuse of those least able to protect themselves. Researchers have an ethical responsibility to uphold the integrity of these ethical standards. Failure to do so today may have a devastating impact on humanity in the future.
Keywords: Acquired Immunodeficiency Syndrome - diagnosis, Acquired Immunodeficiency Syndrome - therapy, Anti-Bacterial Agents - pharmacology, Codes of Ethics, Developing Countries, Ethical Relativism, Ethical Theory, Ethics, Ethics, Medical, Ethics, Professional, HIV Seropositivity, Human Experimentation, Sexually Transmitted Diseases - drug therapy
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Clinical Research
Impact of Smovey Vibration Versus Dumbbell Resistance on Muscle Activation in WomenMed Sci Monit In Press; DOI: 10.12659/MSM.946567
Clinical Research
Five-Year Impact of Weight Loss on Knee Pain and Quality of Life in Obese PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.946550
Clinical Research
Butorphanol Tartrate Nasal Spray for Post-Cesarean Analgesia and Prolactin SecretionMed Sci Monit In Press; DOI: 10.12659/MSM.945224
Database Analysis
Role of the Carhart Effect and Outcomes from Surgery: A Retrospective Study of 532 Patients with Conductive...Med Sci Monit In Press; DOI: 10.12659/MSM.947061
Most Viewed Current Articles
17 Jan 2024 : Review article 6,963,045
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,086
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 23,449
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,141
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912